Survodutide · Research brief

Survodutide Peptide: Research Overview, Purity Data and Where to Buy

Real Peptides Research TeamEditorial

Updated October 14, 202611 min read

56 WORDS

Short answer

Most people searching for survodutide assume it's a semaglutide variant wearing a different label. It isn't. Survodutide (development code BI 456906) is a dual agonist that activates the glucagon receptor and the GLP-1 receptor from a single molecule, and the glucagon half of that pairing, not the GLP-1 half, is what makes the compound scientifically unusual.

Key takeaways

Survodutide (BI 456906) is a dual glucagon receptor and GLP-1 receptor agonist developed by Boehringer Ingelheim with Zealand Pharma, and it is not an FDA-approved drug product.
The glucagon receptor arm acts primarily on the liver, raising hepatic fatty acid oxidation and energy expenditure, which is why liver endpoints feature heavily in the published literature.
Acylation with a lipid side chain allows albumin binding, which slows renal clearance and underpins the weekly administration schedules used in clinical trial designs.
Lyophilised peptide material should be stored sealed at -20°C or below and protected from light; material in solution belongs at 2-8°C with a working window of weeks.
A credible certificate of analysis pairs RP-HPLC area-percent purity with mass spectrometry and prints the lot number matching the vial received, which is why our documentation is published per lot at /coas/ .
Preclinical survodutide papers are indexed under the code BI 456906, so searching only the current name returns an incomplete literature set.

We supply research-grade peptides to laboratories, and we've learned which questions actually matter when a compound like survodutide lands on a procurement list: sequence fidelity, lot-matched analytical data, and cold chain integrity. All products are sold for laboratory research use only and are not for human consumption.

What is survodutide?

Survodutide (BI 456906) is an acylated, glucagon-backbone peptide developed by Boehringer Ingelheim with Zealand Pharma, engineered as a dual glucagon receptor and GLP-1 receptor agonist. Published work has examined it in obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis. Laboratories source survodutide as a lyophilised powder with per-lot purity documentation attached.

The common oversimplification is filing survodutide alongside semaglutide and tirzepatide as another weight-regulation peptide. That framing loses the mechanism entirely, because glucagon receptor agonism acts on hepatic substrate handling and energy expenditure, pathways that GLP-1 and GIP agonists don't engage directly. This hub covers the receptor pharmacology, what the published survodutide literature examines, laboratory handling and storage, how per-lot purity gets verified, and the regulatory status that governs how the compound may be sold.

A dual agonist, not another GLP-1 analogue

Survodutide binds and activates two distinct receptors: the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). GLP-1R activation is the familiar arm, the incretin pathway that enhances glucose-dependent insulin secretion and slows gastric emptying. GCGR activation is the unfamiliar one, and it runs largely through the liver, where glucagon signalling raises hepatic fatty acid oxidation and energy expenditure while simultaneously driving glycogenolysis and gluconeogenesis.

That last clause is the part generic overviews skip. Glucagon receptor agonism increases hepatic glucose output, which in isolation is the opposite of what a metabolic research compound wants. The GLP-1 arm is what counterbalances it. So the pharmacology of survodutide isn't really about either receptor alone. It's about the ratio of agonist potency across the two, and that ratio is a deliberate engineering decision rather than an accident of sequence.

Structurally, the molecule carries a lipid side chain. That acylation allows reversible binding to circulating albumin, which slows renal clearance and extends plasma residency, which is why clinical investigators were able to build trial designs around weekly administration at all. Remove the fatty acid and you're left with a very short-lived peptide.

In our experience fielding technical questions from labs, this is the most common misunderstanding we encounter. Researchers expect survodutide to behave like a GLP-1 analogue in cell-based assays, then find that hepatocyte and energy-expenditure endpoints move differently. The glucagon arm is the reason.

What the published literature examines

Survodutide appears in the peer-reviewed record under two names, survodutide and the development code BI 456906, and a combined index of both is retrievable on PubMed. Searching only the current name misses a meaningful slice of the preclinical work, which was published before the compound was renamed.

Three research threads dominate the indexed literature.

Preclinical pharmacology. Receptor-selectivity characterisation, pharmacokinetics, and rodent work on body weight, food intake, hepatic lipid content and energy expenditure, indexed largely under the development code (PubMed).

Body-weight regulation. Clinical investigation in adults with overweight or obesity, where tolerability and stepwise escalation schedules were central design concerns (PubMed).

Liver endpoints. Investigation in metabolic dysfunction-associated steatohepatitis, previously called NASH, using histological and fibrosis-stage endpoints. This is where the glucagon arm has its clearest mechanistic rationale, since hepatic lipid oxidation is a direct downstream consequence of GCGR signalling (PubMed).

We'd rather point researchers at the index than paraphrase outcomes, and that's a deliberate editorial choice. Paraphrased efficacy figures are exactly where most survodutide content online goes wrong, usually by compressing a trial's primary endpoint into a headline number stripped of its comparator, duration and population. Read the papers in their original form.

Gastrointestinal tolerability recurs as a theme across published incretin-class trial reports, and survodutide is investigated within that context rather than outside it. Nothing in the literature constitutes guidance for use in people.

Laboratory handling, storage and cold chain basics

Survodutide ships as a lyophilised, freeze-dried powder, and in that dry state it's more forgiving than most researchers expect. The cake tolerates short ambient excursions during transit. Once in solution, the chemistry changes and the stability clock starts.

Standard laboratory practice for an acylated peptide like survodutide looks like this:

Sealed lyophilised material stored at -20°C or below, desiccated and protected from light.
Material in solution held refrigerated at 2-8°C, with a working window measured in weeks rather than months.
Aliquoting before freezing. Repeated freeze-thaw cycling is a leading cause of silent potency loss in lipidated peptides.
Gentle handling only. Vortexing and vigorous shaking create shear and air-liquid interface stress, which promotes aggregation and surface denaturation. Swirl, don't shake.
Low-binding polypropylene labware. Lipidated peptides adsorb to glass and to standard plastic surfaces, and that loss is invisible.

Here's the part that catches labs out. A temperature excursion doesn't change how the vial looks. No colour shift, no visible precipitate, no detectable difference by eye. Arrival condition and cold-chain documentation therefore matter more than visual inspection ever will, which is why our team logs pack condition on cold-chain shipments rather than relying on the receiving researcher to spot a problem that doesn't present visually.

If an animal-health question brought you to this page, that conversation belongs with a licensed veterinarian. Survodutide is not a veterinary product, and nothing here is handling guidance for living subjects.

How per-lot purity data gets verified

Purity on a peptide certificate of analysis means one specific thing: area-percent purity by reverse-phase high-performance liquid chromatography (RP-HPLC), typically read at 214 nm, the wavelength where the peptide bond absorbs. A second, orthogonal test, mass spectrometry by ESI-MS or MALDI-TOF, confirms that the observed molecular weight matches the theoretical mass calculated from the sequence.

Both tests are necessary, and here's why either alone is insufficient. An HPLC trace can read beautifully while the dominant impurity is a deletion sequence, a chain missing a single amino acid, co-eluting almost directly beneath the main peak. Chromatography frequently can't resolve it. Mass spectrometry can, because an absent residue shifts the mass by a known, predictable amount. A survodutide certificate carrying a chromatogram but no mass spec result is half a certificate.

A usable certificate shows the lot number printed on the vial you physically received, the test date, the chromatogram trace itself rather than just a summary figure, the mass spec result, and the testing laboratory. Water content by Karl Fischer, residual acetate and endotoxin testing are optional additions that tell you more about synthesis and workup quality.

Across the supplier certificates our team has reviewed, the most common defect isn't a weak purity figure. It's a certificate with no lot number, which makes it unmatchable to the vial in front of you. An unmatchable certificate for survodutide or anything else is a marketing document, not analytical data. Every lot we supply is small-batch synthesised with exact amino-acid sequencing, and the documentation is published lot by lot on our certificates of analysis page.

Regulatory status and ordering survodutide for research

Survodutide is not an FDA-approved drug product. It is an investigational compound in clinical development, which means no approved labelling, no approved indication, and no lawful pathway for sale as a therapeutic. Material supplied by research vendors, ours included, is a chemical reagent intended for in vitro and preclinical laboratory work. All products are sold for laboratory research use only and are not for human consumption. No quantity guidance for people appears anywhere on our site, and that absence is deliberate rather than an oversight.

Institutional buyers should also hold the distinction between research-grade and pharmaceutical-grade material clearly in mind. Research-grade survodutide is synthesised and analytically verified for laboratory use. It is not manufactured under the quality management systems required for clinical trial material, and the two categories aren't interchangeable regardless of how closely their purity figures appear to match.

For sourcing, our survodutide product page carries the current lot specification and links directly to the matching certificate. Labs running metabolic pathway work alongside this compound frequently order MOTS-c for mitochondrial endpoints or 5-Amino-1MQ for NNMT-related work, and the full research peptide catalogue sits beside our per-lot certificates so documentation can be checked before a purchase order is raised rather than after delivery. Survodutide requires cold-chain packing, so shipment timing matters for labs without weekend receiving.

How it compares with other incretin research peptides

Researchers evaluating survodutide usually want to know how its receptor profile differs from the better-known incretin compounds on a supplier catalogue. This table maps receptor targets against the research questions each compound is typically used to probe.

Research Peptide	Receptor Targets	Dominant Research Focus in the Literature	Bottom Line for Lab Sourcing
Survodutide (BI 456906)	GCGR and GLP-1R dual agonist	Hepatic lipid handling, energy expenditure, MASH and fibrosis endpoints, body-weight regulation	Choose it when the glucagon receptor arm is the variable you're actually interested in; appetite-only models won't reveal what makes the molecule distinct
Tirzepatide	GIP and GLP-1R dual agonist	Glycaemic control, insulin sensitivity, adipose signalling	Different dual pairing entirely; GIP work doesn't transfer to glucagon receptor questions and shouldn't be used as a proxy
Semaglutide	GLP-1R single agonist	Incretin signalling, gastric emptying, satiety pathways	The cleanest single-receptor comparator; useful as a GLP-1-only control arm against dual agonist designs
Retatrutide	GIP, GLP-1R and GCGR triple agonist	Combined incretin and glucagon pathway investigation	Overlaps with survodutide on the glucagon arm but adds GIP, which complicates attribution when isolating a single mechanism

What If: Common Lab Sourcing Scenarios

What if a vial arrives warm or the cold pack has fully melted?

Document the arrival condition with a photograph and contact the supplier before opening the vial. Lyophilised material is comparatively robust to brief ambient exposure, so a melted gel pack is not automatically a ruined lot, but the decision requires knowing transit duration and ambient conditions. Degradation in dry peptide produces no visible change, so inspection by eye resolves nothing. A supplier who logs pack-out temperature and ship date can tell you whether the excursion falls inside the material's documented tolerance.

What if the certificate of analysis has no lot number on it?

Treat it as unverified material and request lot-matched documentation. A certificate without a lot number cannot be tied to the vial on your bench, which means it certifies nothing about what you actually received. This is the most frequent documentation gap we see across the research peptide market. Generic certificates get reused across multiple synthesis runs, and purity varies run to run even within the same facility.

What if the powder looks like a thin film rather than a fluffy cake?

Note it and compare against the certificate, but don't assume failure. Lyophilised appearance varies with fill volume, excipient content and the freeze-drying cycle used, and low-fill vials of peptide commonly present as a thin film or a barely visible residue on the vial wall. Appearance is a weak indicator of quality either way. The analytical data is the evidence; the visual is not.

What if a seller offers survodutide with no analytical documentation at all?

Walk away. Peptide synthesis produces truncated and deletion sequences as a routine byproduct, and without RP-HPLC and mass spectrometry data there is no way to know what fraction of the vial contains the intended sequence. Undocumented survodutide introduces an uncontrolled variable into every experiment downstream of it, which is a far more expensive problem than paying for verified material in the first place.

The uncomfortable truth about purity claims

Let's be direct about this: a purity percentage printed on a web page is worth nothing on its own. It isn't a specification, it's a claim, and it's trivially easy to publish. What carries weight is a lot-numbered certificate with the actual chromatogram trace, a mass spectrometry result confirming theoretical mass, a test date and a named testing laboratory. Two suppliers can both advertise 99% and deliver materially different products, because one figure came from an orthogonally verified lot and the other came from a marketing template. Ask which lot the number belongs to. The answer separates the market quickly.

Survodutide is the clearest current example of a peptide whose scientific interest sits in what it does to the liver rather than what it does to appetite. Frame it as a glucagon receptor tool that happens to carry a GLP-1 arm, and the published literature reads coherently. Frame it as a semaglutide substitute, and you'll build experiments measuring endpoints that were never the point. The mechanism dictates the model, not the other way round. All products are sold for laboratory research use only and are not for human consumption.

References

Peer-reviewed sources on Survodutide indexed in PubMed, listed for research context. Real Peptides supplies Survodutide for laboratory research use only.

A review of survodutide: a new dual acting agonist. Minerva endocrinology, 2026. PMID 41855048. doi:10.23736/S2724-6507.26.04406-4
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. Diabetes, obesity & metabolism, 2025. PMID 40922121. doi:10.1111/dom.70105
Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis. Indian journal of endocrinology and metabolism, 2025. PMID 40688625. doi:10.4103/ijem.ijem_366_24
Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England journal of medicine, 2026. PMID 42253238. doi:10.1056/NEJMoa2600751
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1). Diabetes, obesity & metabolism, 2026. PMID 41187967. doi:10.1111/dom.70196
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine, 2026. PMID 42252333. doi:10.1038/s41591-026-04479-3
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. Diabetes, obesity & metabolism, 2026. PMID 42331726. doi:10.1111/dom.70861
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). Obesity (Silver Spring, Md.), 2025. PMID 39495965. doi:10.1002/oby.24184

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

Survodutide (development code BI 456906) is a dual agonist that activates both the glucagon receptor and the GLP-1 receptor from a single acylated peptide molecule. Semaglutide activates only the GLP-1 receptor. The practical difference is the glucagon arm, which acts on hepatic fatty acid oxidation and energy expenditure, pathways a GLP-1-only agonist does not engage directly. Both compounds are supplied by research vendors as reagents, not as therapeutics.

It binds and activates the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). GLP-1R activation drives glucose-dependent insulin secretion and slows gastric emptying; GCGR activation acts mainly on the liver, raising fatty acid oxidation and energy expenditure while also increasing hepatic glucose output. The balance of potency at the two receptors is the critical design variable, because the GLP-1 arm counteracts the glycaemic effect of the glucagon arm.

No. Survodutide is an investigational compound in clinical development and holds no FDA approval, no approved labelling and no approved indication. Research suppliers sell it strictly as a chemical reagent for in vitro and preclinical laboratory work. It cannot lawfully be marketed or sold as a therapeutic product.

Research-grade peptides are sold to researchers and laboratories for in vitro and preclinical use only, never for human or veterinary consumption. Suppliers typically require that the purchaser is acquiring the material for legitimate laboratory research. Because the compound is investigational, there is no legal consumer or patient channel for it anywhere.

Orders are placed through the supplier's product page, where the current lot specification and the matching certificate of analysis should both be visible before purchase. Our survodutide listing links to its per-lot documentation at /coas/, and institutional buyers commonly check that documentation first so the purchase order references a verified lot. Pricing varies by supplier, quantity and purity grade.

At minimum it should show RP-HPLC area-percent purity with the chromatogram trace included, a mass spectrometry result confirming the observed molecular weight against theoretical mass, the test date, the testing laboratory and the lot number matching the vial received. Water content by Karl Fischer, residual acetate and endotoxin results are useful additions. A certificate with no lot number cannot be matched to your material and should be treated as unverified.

Reverse-phase HPLC separates by hydrophobicity, and a deletion sequence missing a single amino acid often co-elutes extremely close to the target peak. That impurity can hide inside what looks like a clean main peak. Mass spectrometry detects it because an absent residue shifts molecular weight by a known amount. Running both tests is what makes a purity figure meaningful.

Sealed lyophilised powder is generally held at -20°C or below, desiccated and protected from light. Material in solution is refrigerated at 2-8°C with a working window measured in weeks. Aliquot before freezing to avoid repeated freeze-thaw cycles, which degrade acylated peptides without producing any visible change in the vial.

Research-grade material is synthesised and analytically verified for laboratory use, with purity confirmed by chromatography and mass spectrometry. Pharmaceutical-grade material is produced under GMP quality management systems with full batch traceability, environmental controls and regulatory oversight of the manufacturing process. The two are not interchangeable even when their stated purity figures look similar, because the difference lies in the manufacturing system rather than the final assay.

No. Survodutide is a dual agonist at the glucagon and GLP-1 receptors, while retatrutide is a triple agonist that adds GIP receptor activity to those two. They overlap on the glucagon arm, which means retatrutide cannot be used as a clean proxy when the research question is about isolating glucagon receptor effects, since the GIP component confounds attribution.

BI 456906 is the Boehringer Ingelheim development code assigned before the compound received its current name. Much of the preclinical pharmacology was published under the code, so a PubMed search using only the current name returns an incomplete literature set. Searching both terms together retrieves the full indexed record.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA